Figure 1
![Figure 1. TFS of 449 patients with CLL according to the sFLC assay. Kaplan-Meier curves show the 3-year probability of remaining treatment-free for CLL cases subdivided into 3 groups based on their normal [normal sFLC(κ/λ)] or abnormal κ or λ sFLC ratio. The 3-year TFS was significantly lower in patients with κ or λ sFLC(κ/λ).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/118/24/10.1182_blood-2011-04-345587/4/zh89991182680001.jpeg?Expires=1724262496&Signature=B7YHW4cYR3uyxr28H6M9b3AOjgnXD35j-UHOSQuGri87I~d3VPzSQ7~hkv7b9oqV95w0dznSShNILntbE8CYVMdJzeVDVhMWyG6Nge0e4cW62ErJT7xD-XTxnwJnSx~OAlYum1oGjyTgGi5Id1tqjVauLEyYHSMp2K9efGGyDa5f9FBSpYqaSpxsTv9vt0JLink3GsthonDXKNPn--Vk4tEXZLtAWCwNZmyTVq7pgC0ljIo4Gi3U5mVP-jlXuGxQQz4IyQuAJwh-edm5OAZ9kaZv1vuWnR534mUCHWZOwNMqlqk5NO7FQSf3ANRIbhYBtHbNJ-NtJ7QbC1eu-~k9nw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
TFS of 449 patients with CLL according to the sFLC assay. Kaplan-Meier curves show the 3-year probability of remaining treatment-free for CLL cases subdivided into 3 groups based on their normal [normal sFLC(κ/λ)] or abnormal κ or λ sFLC ratio. The 3-year TFS was significantly lower in patients with κ or λ sFLC(κ/λ).
